Summarize a Drug Interaction Study PDF with AI Locally for a Pharmacist Evaluating a New Medication's Safety Profile

When a pharmacist evaluates a new medication's safety profile, the prescribing information alone rarely tells the whole story. The pre-approval drug–drug interaction (DDI) study PDF contains the supporting data—AUC ratios, confidence intervals, probe substrates, and study design—that explain how the drug should be dosed, monitored, or contraindicated. Already a useful task, summarizing these dense study PDFs with AI becomes even more efficient when the processing happens locally. This article explains a local-first, bring-your-own-key (BYO) approach: the PDF is parsed on the device, only extracted text is sent to a model endpoint you choose, and the original file never leaves your control.

Quick Answers

Why Local Processing Matters for DDI Study Review

A phase 1 DDI study is a commercial-in-confidence document containing unpublished trial results. If the PDF also includes participant-level data, the EU General Data Protection Regulation (GDPR) applies directly; if it contains only aggregate tables, the file is still governed by contractual confidentiality and clinical-trial disclosure obligations. Uploading it to a general-purpose web tool means the file passes through a vendor server, often outside the reviewer's jurisdiction—a difficult position to reconcile with data minimization and with an institution's duty of care.

The local architecture addresses both problems. The PDF is parsed entirely on-device using open-source libraries such as pdf.js, so the raw file is never transmitted. In a bring-your-own-key setup, the browser calls the model provider directly with the user's own API key, eliminating a third-party proxy server in the middle. The only data that leaves the device is the extracted text payload sent to the model provider you select—the same confidentiality rules that apply to any study excerpt shared with a collaborator.

A Reproducible Local Summarization Workflow

The following workflow reconciles speed with confidentiality. Tooling can vary; the architecture is what matters.

Step 1: Obtain the Version-Controlled PDF

Work from the final, versioned PDF of the study report or the clinical pharmacology section of the submission. Record the version, date, and document reference in your review trail. An AI summary is only as reliable as the source file it starts from.

Step 2: Run a Local Redaction/Sanitization Pass (When Needed)

Proper redaction is not drawing black boxes over visible text. A sanitization pass physically removes metadata, hidden text, comments, and embedded objects from the file. This is required when the PDF contains patient-identifiable information, unpublished trial data, or commercial-in-confidence material.

Perform this step offline. An upload-based redaction tool reintroduces the exact risk it claims to remove: the file must cross a third-party server to be "protected." After sanitization, review the cleaned PDF page by page before moving forward.

Step 3: Choose a Local Processing Architecture

The trade-offs are straightforward. Browser-based tooling offers frontier-model quality and convenience but depends on your chosen API provider's confidentiality terms. Offline runners provide the strongest confidentiality because no network request occurs at all. On-premise deployments suit institutions that require audited infrastructure and formal compliance workflows.

One operational caution: an API key stored in browser storage presents an XSS risk on shared devices. Prefer tools that keep keys in memory or use an institutional credential vault, and never use browser-stored keys on a shared workstation.

Step 4: Prompt for Interaction-Focused Output

A generic "summarize this PDF" prompt produces a generic summary. For a DDI evaluation, the prompt should force extraction of the exact elements a safety review depends on. This prompt is a practical starting point:

You are reviewing a phase 1 drug–drug interaction study for a medication
safety assessment. For each interaction result, report:
- the geometric mean ratio (GMR) and 90% confidence interval for AUC and Cmax
- the study design (sequence, population, dose regimen, duration)
- the probe substrate and the enzyme/transporter pathway investigated
- the original sentence in the PDF that supports each claim

Do not add clinical significance judgments. Flag any result whose 90%
confidence interval crosses the 0.80–1.25 boundary.

Step 5: Verify Before Deciding

The AI summary is a triage document. Before applying any finding to a clinical decision, open the original PDF and verify each claim against the source tables. The protocol in the final sections below is designed for exactly this step.

Interpreting What a DDI Study Actually Contains

Technical depth matters because the AI summary merely condenses the study's content. To verify well, you need to understand the underlying pharmacology.

Most DDI studies use one of two designs:

• Fixed-sequence studies, in which the substrate is given alone, then the interacting drug is dosed to steady state, and the substrate is re-administered. These are common for CYP inhibition assessments.
• Crossover studies, in which each participant receives both treatment sequences, enabling within-subject comparison.

Probe substrates are chosen for pathway selectivity: midazolam for CYP3A4, S-warfarin for CYP2C9, caffeine for CYP1A2, omeprazole for CYP2C19, and dextromethorphan for CYP2D6. Transporter pathways such as OATP1B1 are typically probed with statins like rosuvastatin or pitavastatin.

The key output is the geometric mean ratio of systemic exposure (AUC) between co-administration and substrate alone, with a 90% confidence interval. The FDA guidance on drug interaction studies—and the corresponding EMA guideline—frame the evaluation boundary: when the 90% CI of the AUC ratio falls outside 0.80–1.25, an interaction is considered detectable and potentially label-relevant. Clinical significance then depends on the substrate's therapeutic index and the magnitude of the change. For narrow-therapeutic-index drugs, regulators may apply a narrower boundary.

A pharmacist evaluating a new medication's safety profile needs these numbers to answer a practical question: could co-administration with a known perpetrator push a vulnerable patient outside the safe exposure range? Published repositories such as the University of Washington Drug Interaction Database can be consulted to check whether the observed ratios are consistent with what is already known about the pathway.

Worked Example: A New Kinase Inhibitor and Midazolam

XYZ-123 is a fictional compound; the numbers below illustrate a pattern a pharmacist will frequently encounter.

Consider a hypothetical phase 1 study in which the new kinase inhibitor XYZ-123 is dosed to steady state, followed by a single 2 mg oral dose of midazolam. The study report shows a midazolam AUC geometric mean ratio of 3.4, with a 90% confidence interval of 2.9 to 4.0.

Because the lower bound (2.9) is well above the 1.25 threshold, the result identifies XYZ-123 as a strong CYP3A4 inhibitor. A well-prompted AI summary will surface the ratio, the CI, and the supporting sentence in the original text.

What the AI summary cannot do is decide the label response. The pharmacist must then check the proposed label language: does it recommend avoiding strong CYP3A4 substrates, reducing substrate doses, or adding monitoring? Does the study include a second analysis in patients rather than healthy volunteers? Is there a limitations paragraph that weakens the conclusion for real-world populations? Answering these questions requires reading the original discussion and limitations text—which is why every AI-generated claim must be traceable to a page and sentence.

This example also illustrates a common pattern: additional probe results, such as CYP2C8 or OATP1B1 tables, are often placed in appendices after the main figures. Models with long context windows may still compress or lose that trailing content. Chunk the PDF by section—Methods, Results, Appendix tables—and preserve page references in the prompt.

Fact-Checking Protocol for AI Summaries

Use the AI output for what it does well: surfacing the study's key numbers and claims quickly. Then apply a fixed checklist to the source PDF:

1. Confirm the study design—fixed-sequence or crossover; healthy volunteers or patients.
2. Confirm the magnitude terms—AUC ratio, Cmax, clearance—exactly as reported in the tables.
3. Confirm the confidence intervals and whether the 80–125% boundary is crossed.
4. Confirm the population description—age, renal/hepatic function, comedications—and any exclusions.
5. Read the limitations paragraph; models frequently compress or omit qualification language.
6. Discard any claim in the AI summary that cannot be traced to an original sentence.

Because the local pipeline keeps the PDF on your device, verification is direct. Maintain a documentation trail: model name and version, prompt text, date, and the source PDF's hash. This makes the summary reproducible for institutional review or inspection.

Limitations and Safeguards

Local processing does not change the underlying limits of language models:

• Hallucinated results. Models may invent plausible-sounding numbers. This is why the prompt demands supporting quotes and why the verification step is non-negotiable.
• Silent truncation. If the PDF exceeds the context window, the model may omit the appendix where DDI results are reported. Mitigate by chunking and by using models with large context windows.
• Guidance drift. AI output reflects training data and the provided document. FDA and EMA guidance documents, not the model, are the decision anchor for interpreting interaction magnitude.
• Institutional policy. Some institutions prohibit sending clinical data to external model providers even in text-only form. In that case, use a fully offline runner or an on-premise deployment rather than a cloud API.

Consumer web AI tools should still be treated as untrusted for pre-approval drug data. Enterprise cloud arrangements, by contrast, can be acceptable when they include a signed data-processing agreement, private endpoints, and defined regional data residency.

Key Facts

• A local-first pipeline parses the DDI study PDF on-device with open-source libraries such as pdf.js; the original file is never uploaded.
• In a bring-your-own-key setup, the API key stays in browser storage or an institutional vault, and the browser connects directly to the model endpoint.
• Upload-based consumer tools are unsuitable for confidential pre-approval data; GDPR, HIPAA, and contractual duties create accountability that such tools do not provide.
• Proper redaction/sanitization physically removes metadata, comments, and hidden content—and should itself be performed locally.
• Interaction results are evaluated by geometric mean AUC ratios with 90% confidence intervals against the 0.80–1.25 boundary.
• AI summaries require a fact-checking protocol: trace every claim to a source sentence and keep a model/prompt/date documentation trail.
• Summarizing a drug interaction study PDF with AI locally gives a pharmacist evaluating a new medication's safety profile both speed and confidentiality—when the verification step is respected.

References

• U.S. Food and Drug Administration. Guidance for Industry: Drug Interaction Studies—Design, Data Analysis, Implications for Dosing, and Labeling Recommendations. January 2020.
• European Medicines Agency. Guideline on the Investigation of Drug Interactions. CPMP/EWP/560/95/Rev.1, 2012.
• Regulation (EU) 2016/679 (General Data Protection Regulation).
• U.S. Department of Health and Human Services. HIPAA Privacy Rule, 45 CFR Parts 160 and 164.
• Mozilla. pdf.js—An open-source PDF parser and renderer built with web technologies.
• Ollama and LM Studio—local LLM runners available as open-source or freely downloadable tools.
• University of Washington. Drug Interaction Database Program.